protocol
[대역어] 프로토콜
[용어속성] Term
[용어속성] Term
Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
Administered
age
antibiotic
antiviral efficacy
Asthma
Azithromycin
Beta blocker
blinded
block
calcium
cardiovascular
change
changed
chronic
clinical
combination therapy
Control
control group
coordinator
COPD
COVID-19
COVID-19 test
Day
days alive
death
derivative
Diagnosis
Direct Current
discharged
disorder
dissemination
double-blind study
ECG
element
ergot alkaloid
expected
Final
FiO2
generate
Glucose
glucose-6-phosphate dehydrogenase deficiency
guide
hearing loss
hematological
hospital
hospitalisation
Hospitalization
hospitals
Hydroxychloroquine
hypersensitivity
impede
Inclusion
Informed consent
intensive care
Interstitial lung disease
Intervention
intervention group
invasive ventilation
investigated
investigator
Liver disease
lung
maculopathy
medication
mental illness
modulation
myasthenia gravis
negative pregnancy test
network
Neurogenic
neurological
number
objective
offered
outcome
parallel group
participant
Patient
patients with COVID-19
Placebo
pregnant
Primary outcome
problem
protocol
psoriasis
pulmonary
QTc
QTc interval
randomisation
randomised
randomised controlled trial
receive
recruited
recruitment
reduce
Registered
reported
respiratory infections
retinopathy
risk
Sample size
sequence
significantly
Sponsor
Standard
standard care
standard treatment
status
Stratification
Study protocol
the patient
therapy
treated
Treatment
Trial
Visual field
website
women
[DOI] 10.1186/s13063-020-04409-9 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04409-9 PMC 바로가기 [Article Type] Letter
Radiotherapeutic management of brain tumours during the COVID-19 pandemic
Technical Note
[키워드] Algorithm
article
Brain
Brain tumors
Care
coronavirus disease
COVID-19
COVID-19 pandemic
database
English language
guidelines
healthcare facility
Healthcare system
help
hospital
management
material
outcome
pandemic
Patient
protocol
Radiotherapy
reducing
regimen
Safe
Treatment
tumour
[DOI] 10.1017/S1460396920000394 PMC 바로가기 [Article Type] Technical Note
[DOI] 10.1017/S1460396920000394 PMC 바로가기 [Article Type] Technical Note
Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 6-minute walking distance
actual
Alpha
analyst
Anluohuaxian
antiviral drugs
brand
bronchial asthma
Care
change
changes
Chinese
Chinese herbal medicines
chronic obstructive
Colchicine
Combined
completion
Compliance
composed
computer tomography
Confirmed
connective tissue
control group
Coronavirus disease 2019
COVID-19
criteria
Cyclophosphamide
cytokine
diagnosed
dissemination
distribution
drug
Efficacy and safety
element
Endocrine
enrolled
Estimated
evaluate
expected
experimental group
explained
facilitate
fibrosis
glucocorticoid
groups
hepatic fibrosis
High-resolution
history
Hormones
HRCT
Huoshenshan Hospital
Imatinib
include
indicate
interferon-γ
interstitial
Interstitial lung disease
investigators
involved
IWRS
Kidney disease
lactating
liver
lobular
lung
maximum
Mental Disorders
minimum
multicenter
Nasopharyngeal swab
Necrosis
negative
neurologic
Nintedanib
nodule
not blinded
nucleic acid test
number
objective
open label
outcome
outcome assessors
participant
Participants
Pathogenesis
pathway
Patient
pharmaceutical
pill
professional
proportion
protocol
provided
pulmonary
pulmonary disease
pulmonary fibrosis
random
randomised
randomised controlled trial
randomization
randomization system
Randomized
Randomized controlled trial
randomly divided
RCT
recruitment
Research
research drug
respiratory specimen
Sample size
Science
second
selected
severe COVID-19
sputum
statistical
status
Study protocol
subject
technology
therapeutic drug
Tongji Hospital
treated
Treatment
treatment group
Trial
Union Hospital
university
variety
website
West
Wuhan
Year
[DOI] 10.1186/s13063-020-04399-8 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04399-8 PMC 바로가기 [Article Type] Letter
2019-nCoV: Measures Adopted at the Departments of Oral Surgery and Radiology during the Period of an Uncontrolled Transmission Increase
Communication
[키워드] 2019-nCoV
2019-nCoV infection
applied
Contact
Contamination
Coronavirus infections
cross
dental
Dental care
Department
described
equipment
increase
infection control
Isolation
management protocol
Maxillofacial
measure
Münster
Mutation
non-infected
oral
pandemic
patients
Period
Prevent
preventive measure
professional
Protective
protocol
radiology
reduce
required
Spread
surgery
Transmission
treated
uncontrolled
university
[DOI] 10.3390/dj8020057 PMC 바로가기 [Article Type] Communication
[DOI] 10.3390/dj8020057 PMC 바로가기 [Article Type] Communication
Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] activity
adverse event
allergic reaction
anti-SARS-CoV-2
anti-SARS-CoV-2 antibody
Anti-SARS-CoV-2 plasma
Anti-viral
blinded
Blood
blood product
center
Chest radiography
Clinical improvement
Clinical outcome
clinical status
clinical trial
clinician
collected
Columbia University
control arm
convalescent plasma
coronavirus
COVID-19
COVID-19 symptom
criteria
cumulative
Date
defined
Dilution
discharge
dissemination
Donor
ECMO
Efficacy
Efficacy and safety
element
evaluate
Evaluating
Evidence
extracorporeal membrane oxygenation
hazard
hazard ratio
HBV
HCV
HIV
hospital
Hospitalized
hospitalized patient
IgA deficiency
immune
incidence
include
Infection
Influenza
Invasive mechanical ventilation
mechanical ventilation
multi-organ failure
nasopharyngeal
Nasopharyngeal swab
New York
Non-invasive
number
objective
occur
oropharyngeal swab
outcome
oxygen saturation
participant
Participants
patients hospitalized
PCR test
PCR-negative
per-protocol analysis
peripheral capillary
plasma
platform
post-hoc analysis
Pregnancy
primary endpoint
protocol
randomization
Randomized
Randomized controlled trial
randomized, controlled trial
randomly permuted block
receive
Registered
Remdesivir
requiring high-flow oxygen
requiring supplemental oxygen
Research
Respiratory failure
retrospective
Ritonavir
safety endpoint
Sample size
SARS-CoV-2
SARS-CoV-2 antibody
SARS-COV-2 infection
screened
Serious Adverse Event
seven-point ordinal scale
severe COVID-19
severe SARS-CoV-2
severely ill adult
single-center
spike trimer
SpO2
status
study participant
study period
Study protocol
supplemental oxygen
tested
therapy
transfused
Treatment
treatment for COVID-19
Trial
undergo
USA
Version
Volunteer
Wald test
website
with COVID-19
World Health Organization
ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter
Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples
Brief Report
[키워드] biosafety
Chemical
clinical
clinical sample
collected
Contact
coronavirus
coronavirus disease
COVID-19
COVID-19 patients
diagnostic
effective
European
evaluated
extraction buffer
French
inactivation
Infectious virus
Laboratory
less
log
lysis buffer
molecular
nasopharyngeal sample
Patient
protocol
reduce
reduction
risk
RNA extraction
Sample
SARS-CoV-2
supernatant
tested
were used
[DOI] 10.3390/v12060624 PMC 바로가기 [Article Type] Brief Report
[DOI] 10.3390/v12060624 PMC 바로가기 [Article Type] Brief Report
Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
6 hour
activity
Analysis
Antiviral effect
blinded
Chloroquine
Complication
contraindication
Control
control group
COVID-19
COVID-19 patient
COVID-19 PCR test
COVID-19 positive patient
Date
death
determine
Diabetes Mellitus
dissemination
dose
Dual therapy
Efficacy
element
Elimination
expected
Follow-up
greater
Hospital admission
hospital discharge
Hydroxychloroquine
hypertension
inherent
Intervention
Intubated
invasive mechanical
management
Mechanical
mechanical ventilation
medication
MERS
monotherapy
nitazoxanide
number
obesity
objective
Older
outcome
parallel group
participant
Patient
patients with COVID-19
PCR test
percentage
Placebo
positive patients
Presence
protocol
QT interval
QTc
randomised
randomised controlled trial
Randomized
Randomly
reached
receive
recruited
recruitment
reducing
required
risk factor
Sample size
SARS-CoV-2
sealed
Seven
state
status
Study protocol
therapy
Toluca
treat
treated
Treatment
treatment regimen
Trial
Ventilation
ventilatory support
virus
website
[DOI] 10.1186/s13063-020-04448-2 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04448-2 PMC 바로가기 [Article Type] Letter
A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol
Letter
[키워드] 1:1
24 hour
28-day mortality
activated
acute respiratory distress syndrome
Administered
Admission
adverse effect
age
albumin
allergic
allocation concealment
Anticoagulant
apheresis
approval
approved
assessment
Basel
block size
C-reactive protein
category
changes in
city
Coagulopathy
Control
COVID-19
COVID-19 disease
criteria
Cytokine release syndrome
D-dimer
defined
disease
dissemination
drug
eight
element
Enrollment
evaluate
evaluated
ferritin
fibrinogen
first dose
FIVE
food
function
group
ICU
ICU admission
ill patient
Improving
Inc.
Inflammatory
ingredient
intensive care
intensive care unit
International
Intervention
intervention group
intubation
IRB
ISRCTN
KDIGO
King
Kingdom
Laboratory
lack
lactate dehydrogenase
life threatening
life-threatening
Life-threatening COVID-19
marker
measure
Mild
Ministry of Health
Multicenter trial
Multisystem organ failure
National
negative RT-PCR
normalized
number
objective
occur
on mechanical ventilation
Open-label
outcome
Palliative care
participant
Participants
Patient
patients
performed
pilot study
plasma
primary site
Prothrombin time
protocol
Qiagen
randomization
randomize
Randomized
Randomized controlled trial
randomized trial
Real-time PCR
receive
receiving
recommendations
recruit
reduce
replaced
Roche
RT-PCR
RT-PCR kit
Safety
Sample size
SARS CoV-2
SARS-CoV-2
SARS-COV-2 infection
Saudi Arabia
secondary
serum
Seven
sodium
SOFA
status
Stratification
Study protocol
supportive care
Switzerland
System
Therapeutic plasma exchange
therapy
TPE
treatment for COVID-19
tumor necrosis factor-alpha
USA
Volume
website
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial
Letter
[키워드] 1:1
48 hour
48 hours
Activation
Administered
adverse event
African
age
allergy
analyzed
Angola
Antiviral
approved
ARMS
Barcelona
baseline
blinded
block
Cerebrovascular disease
chain
chest X-ray
childbearing
chronic
clinical care
clinical trial
co-morbidity
conducted
contraceptive method
control group
coronary disease
cough
country
COVID-19
COVID-19 disease
COVID-19 patient
criteria
Critical
current
CYP3A4
death
detectable
determine
diagnosed with COVID-19
disease
dissemination
dose
double-blind
drug
early treatment
Efficacy
element
Endemic
EudraCT
excluded
eye
Factor
Fever
flow cytometry
Follow-up visit
Frequency
Gabon
global health
groups
history
home visit
Identified
IgA
IgA level
IgG
IgM
immune response
Immunity
immunology
immunomodulatory
IMPROVE
in vivo
Infection
Inflammatory
inhibitor
interfere
investigator
involved
Isolation
Ivermectin
laboratory parameter
Loa loa
magnitude
marker
median
Nasopharyngeal swab
nasopharyngeal swab PCR
negative
neoplasm
Nigeria
no risk
number
objective
outcome
participant
Patient
Patient care
patients
PCR
PCR cycle
physical
Placebo
placebo group
placebo-controlled
Pneumonia
positive
positive SARS-CoV-2 PCR
post-menopausal
Potential
pregnancy test
pregnant women
progression
proportion
protocol
public health
pulmonary
random
randomised
randomised controlled trial
randomization
randomization list
Randomized
Rapid diagnostic test
reaction
receive
recent
recruited
reduce
Registered
renal
resident
risk
Ritonavir
Safe
Sample size
SARS-CoV-2
SARS-CoV-2 RNA
SARS-CoV-2-specific T cell
secondary
sequence
Seroconversion
severe disease
severity
single center
single dose
Spain
status
Study protocol
subject
submitted
surgical
Symptom
symptom onset
the patient
the SARS-CoV-2
threshold
transcriptomics
Transmission
transmission-blocking
Travel
treated patient
treated patients
Treatment
treatment group
Trial
unblinding
Viral load
virus
vulnerable population
website
with mild disease
women
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter